Analgesia (mild), minor procedures: Limited data available; various regimens have been reported; optimal dose not established.
Preterm and term neonates: Oral: 0.1 mL (equivalent to ~3 drops from vial or pacifier dip in cup) of 24% solution placed on the tongue or buccal surface (via oral syringe or pacifier) 2 minutes prior to procedure; dose may be repeated after 1 minute for longer procedures or if analgesia not achieved with the first dose (Bueno 2023; Stevens 2018). Higher doses ranging from 0.2 to 2 mL have also been reported (Kristoffersen 2018; LaFrak 2006; Spruill 2022; Stevens 2016; Stevens 2018), but may not offer additional analgesia. Doses should be limited to <10 doses/day (Johnston 2002; Johnston 2007). Note: Some studies suggest that a combination of nonpharmacologic measures (eg, non-nutritive sucking, swaddling) with sucrose has additive benefit (AAP 2016; Spruill 2022; Stevens 2016; Thakkar 2016).
Analgesia (mild)/Comfort; minor procedures (eg, heel sticks, immunizations, venipuncture, IV line insertion, arterial puncture, insertion of a Foley catheter, lumbar puncture): Limited data available; optimal dose not established:
Infants: Oral: Usual dose: 2 mL of 24% solution administered 1 to 2 minutes before the start of the painful procedure; may be administered as 1 mL in each cheek or allow infant to suck solution from pacifier; effective range: 1 to 2 mL of 12% to 75% solution (AAP [Fein 2012]; Harrison 2010; Kassab 2012; Kassab 2020; Smith 2022). Based on data in preterm infants, some experts suggest that doses should be limited to <10 doses/day (Harrison 2012; Johnston 2007).
There are no dosage adjustments in the manufacturer's labeling.
There are no dosage adjustments in the manufacturer's labeling.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
Frequency not defined.
Cardiovascular: Bradycardia (self-limiting)
Hematologic & oncologic: Oxygen desaturation (premature neonates; spontaneous resolution)
Respiratory: Apnea (brief apnea in premature neonates; spontaneous resolution)
Disease-related concerns:
• Gastrointestinal disorders: Patients should have a functioning gastrointestinal tract; avoid use in patients with gastrointestinal tract abnormalities (eg, esophageal atresia or tracheal esophageal fistula); while necrotizing enterocolitis (NEC) has not been reported with sucrose administration, risk:benefit assessment should be considered in patients at high risk for NEC.
Special populations:
• Neonates: Efficacy in unstable or extremely low birth weight, premature neonates has not been established (LeFrak 2006).
Other warnings/precautions:
• Appropriate use: Avoid use in patients at risk for aspiration; sucrose should not be used for patients requiring ongoing analgesia.
Use with caution in patients who are intubated to avoid gagging and choking; avoid use in paralyzed patients (LeFrak 2006).
Concerns have been raised regarding repeated use of sucrose in patients <31 weeks postconceptual age and neurodevelopmental and physical outcomes. In a randomized, double-blind, placebo-controlled trial, 103 neonates were randomized to receive sucrose (n=53) or sterile water at the beginning of minor procedures; repeat doses were given every 2 minutes for 3 doses or if procedure was longer than 15 minutes, 3 additional doses administered every 2 minutes were allowed. Patients receiving a higher number of sucrose doses had lower scores on motor development and vigor, and alertness and orientation components of the Neurobehavioral Assessment of the Preterm Infant (NAPI) at 36 weeks postconceptual age, lower motor development and vigor at 40 weeks postconceptual age, and higher Neuro-Biological Risk Score (NBRS) at 2 weeks postnatal age (Johnston 2002). The authors conducted a secondary analysis of the raw data and suggested neonates receiving >10 doses of sucrose over a 24-hour period are at a higher risk of poorer neurodevelopmental outcomes (Johnston 2007).
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, oral:
Sweet-Ease® Preserved: 24% (15 mL)
TootSweet™: 24% (0.5 mL, 1 mL, 2 mL, 12 mL)
Solution, oral [preservative free]:
Sweet-Ease Natural®: 24% (15 mL)
No
Oral: For oral use only; sucrose is ineffective when administered via nasogastric tube (Ramenghi 1999). May be administered directly onto tongue or buccal surface or via a pacifier dipped into solution. Analgesic effect is greater when used in conjunction with non-nutritive sucking and/or swaddling (AAP 2016). Dispose of product after use.
Store at 4°C to 32°C (40°F to 90°F). Unused portion should be discarded.
To calm or soothe in times of distress (OTC product: Approved in infants); has also been used for short-term analgesia in neonates during minor procedures (eg, heel stick, immunization, venipuncture, orogastric or NG tube insertion, IM or SUBQ injection, bladder catheterization) and adjunctive analgesia for more complex procedures (eg, circumcision, eye exam for retinopathy of prematurity); provide short-term analgesia in infants during immunization administration and select minor procedures in the emergency department.
Signs of gagging or choking, feeding tolerance/abdominal distention with repeated doses in preterm neonates.
Exact mechanism is not known; it has been proposed that sucrose induces endogenous opioid release.
Onset: Maximum effect: 2 minutes (Blass 1991)
Duration: 3 to 5 minutes (Blass 1991)
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟